Basic Information
REXULTI FILM-COATED TABLETS 0.25MG
TABLET, FILM COATED
Regulatory Information
SIN15768P
August 5, 2019
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XN05AX16
Company Information
LUNDBECK SINGAPORE PTE. LTD.
LUNDBECK SINGAPORE PTE. LTD.
Active Ingredients
Strength: 0.25mg
Detailed Information
Contraindications
**4.3 CONTRAINDICATIONS** Hypersensitivity to the active substance or to any of the excipients.
Indication Information
**4.1 THERAPEUTIC INDICATIONS** Brexpiprazole is indicated in adult patients for: - Use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Efficacy was demonstrated in 6-week trials in adults with MDD who had an inadequate response to antidepressant therapy during the current episode (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). The long-term efficacy of brexpiprazole as adjunctive treatment in MDD has not been established. - Treatment of schizophrenia (see section 5.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) in adults and pediatric patients aged 13 years and older.